Granted Patent
B2
US 12,391,721 · App. 19/025,101 · Granted Aug 19, 2025
Crystal forms of beta-nicotinamide mononucleotide
Inventors:
David J. Livingston (Worcester, MA); Andrew Carr (Hinxton, GB); Philippe Fernandes (Turnhout, BE)
Assignee:
Metro International Biotech, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
Claims (20)
1. A method of formulating a cosmetic composition for topical application to human skin, said method comprising (a) obtaining an amorphous compound of formula (I):
or a salt thereof,
and (b) adding said compound to one or more components to form the cosmetic composition,
wherein:
the composition is an ointment, paste, cream, lotion, or gel; and
the composition is free of absorption enhancers.
2. The method of claim 1 , wherein at least one component for cosmetic topical administration to human skin is a cosmetically acceptable carrier comprising a component selected from the group consisting of a carbohydrate, an antioxidant, and a chelating agent.
3. The method of claim 2 , wherein the carrier comprises a carbohydrate.
4. The method of claim 3 , wherein the carbohydrate is selected from the group consisting of glucose, sucrose, and dextran.
5. The method of claim 2 , wherein the carrier comprises an antioxidant.
6. The method of claim 5 , wherein the antioxidant is selected from the group consisting of ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, and sodium sulfite.
7. The method of claim 5 , wherein the antioxidant is selected from the group consisting of ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and alpha-tocopherol.
8. The method of claim 2 , wherein the carrier comprises a chelating agent.
9. The method of claim 8 , wherein the chelating agent is selected from the group consisting of citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid.
10. The method of claim 1 , wherein the composition further comprises glycerin.
11. The method of claim 1 , wherein the composition further comprises water.
12. The method of claim 1 , wherein the composition is pyrogen-free.
13. A method for enhancing well-being, comprising topically administering a composition made by the method of claim 1 to human skin.
14. A method for achieving a cosmetic effect, comprising topically administering a composition made by the method of claim 1 to human skin.
15. The method of claim 14 , wherein said cosmetic effect is a cosmetic response to symptoms of aging skin, and further wherein the symptoms of aging skin are selected from wrinkles, loss of elasticity, loss of skin volume, and skin discoloration.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 29, 2025
From: LIVINGSTON, DAVID J.; CARR, ANDREW; FERNANDES, PHILIPPE
To: METROBIOTECH LLC
Reel/Frame 071255/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 29, 2025
From: METROBIOTECH LLC
To: METRO INTERNATIONAL BIOTECH, LLC
Reel/Frame 071255/0126 →
Continuity (6)
Continuation
18680133
· May 31, 2024
Continuation
15765325
Provisional Application
62236657
· Oct 2, 2015
References Cited (387)
US 3201389A
· Fujimoto et al.
· 1965
[cited by applicant]
US 3451997A
· Fujimoto et al.
· 1969
[cited by applicant]
US 4411995A
· Whitesides et al.
· 1983
[cited by applicant]
US 7560442B2
· Susilo
· 2009
[cited by applicant]
US 7776326B2
· Milbrandt et al.
· 2010
[cited by applicant]
US 7977049B2
· Sinclair et al.
· 2011
[cited by applicant]
US 8481711B2
· Kaminishi et al.
· 2013
[cited by applicant]
US 9169209B2
· Bair et al.
· 2015
[cited by applicant]
US 9295688B2
· Milbrandt et al.
· 2016
[cited by applicant]
US 9458172B2
· Bair et al.
· 2016
[cited by applicant]
US 9676721B2
· Bair et al.
· 2017
[cited by applicant]
US 9822129B2
· Bair et al.
· 2017
[cited by applicant]
US 9855289B2
· Normington et al.
· 2018
[cited by applicant]
US 9861651B2
· Brown et al.
· 2018
[cited by applicant]
US 9919003B2
· Normington et al.
· 2018
[cited by applicant]
US 9975915B1
· Migaud et al.
· 2018
[cited by applicant]
US 20040224039A1
· Brucker
· 2004
[cited by applicant]
US 20070149466A1
· Milburn et al.
· 2007
[cited by applicant]
US 20080318892A1
· Pickering et al.
· 2008
[cited by applicant]
US 20100047177A1
· Milbrandt
· 2010
[cited by examiner]
US 20120107888A1
· Schmalisch et al.
· 2012
[cited by applicant]
US 20120328526A1
· Kristian
· 2012
[cited by applicant]
US 20130273034A1
· Bair et al.
· 2013
[cited by applicant]
US 20140221319A1
· Sinclair et al.
· 2014
[cited by applicant]
US 20140294805A1
· Bair et al.
· 2014
[cited by applicant]
US 20150258052A1
· Evans et al.
· 2015
[cited by applicant]
US 20160287621A1
· Sinclair et al.
· 2016
[cited by applicant]
US 20160355514A1
· Bair et al.
· 2016
[cited by applicant]
US 20160355539A1
· Migaud et al.
· 2016
[cited by applicant]
US 20170182076A1
· Alvarez et al.
· 2017
[cited by applicant]
US 20170216262A1
· Bair et al.
· 2017
[cited by applicant]
US 20180051253A1
· Chen
· 2018
[cited by applicant]
US 20190328761A1
· Wu et al.
· 2019
[cited by applicant]
US 20200368198A1
· Wu et al.
· 2020
[cited by applicant]
US 20210030908A1
· Mason
· 2021
[cited by applicant]
US 20220098229A1
· Livingston et al.
· 2022
[cited by applicant]
US 20230210746A1
· Bermond et al.
· 2023
[cited by applicant]
US 20240109932A1
· Kremsky et al.
· 2024
[cited by applicant]
CN 101497638A
· 2009
[cited by applicant]
CN 101601679B
· 2011
[cited by applicant]
CN 102876759A
· 2013
[cited by applicant]
CN 104367587B
· 2018
[cited by applicant]
JP S4112737B2
· 1966
[cited by applicant]
JP S4115179B2
· 1996
[cited by applicant]
JP 2007063167A
· 2007
[cited by applicant]
JP 2008501343A
· 2008
[cited by applicant]
WO WO2006072809A2
· 2006
[cited by applicant]
WO WO2006094235A1
· 2006
[cited by applicant]
WO WO2007124447A2
· 2007
[cited by applicant]
WO WO2010135520A1
· 2010
[cited by applicant]
WO WO2011130595A2
· 2011
[cited by applicant]
WO WO2012004917A1
· 2012
[cited by applicant]
WO WO2012031196A1
· 2012
[cited by applicant]
WO WO2012031197A1
· 2012
[cited by applicant]
WO WO2012031199A1
· 2012
[cited by applicant]
WO WO2012094343A1
· 2012
[cited by applicant]
WO WO2012114204A2
· 2012
[cited by applicant]
WO WO2012150952A1
· 2012
[cited by applicant]
WO WO2013085555A2
· 2013
[cited by applicant]
WO WO2013127266A1
· 2013
[cited by applicant]
WO WO2013127267A1
· 2013
[cited by applicant]
WO WO2013127268A1
· 2013
[cited by applicant]
WO WO2013127269A1
· 2013
[cited by applicant]
WO WO2013130943A1
· 2013
[cited by applicant]
WO WO2014059034A2
· 2014
[cited by applicant]
WO WO2014074715A1
· 2014
[cited by applicant]
WO WO2014111906A1
· 2014
[cited by applicant]
WO WO2014146044A1
· 2014
[cited by applicant]
WO WO2015014722A1
· 2015
[cited by applicant]
WO WO2015069860A1
· 2015
[cited by applicant]
WO WO2015070280A1
· 2015
[cited by applicant]
WO WO2015073576A1
· 2015
[cited by applicant]
WO WO2015138969A1
· 2015
[cited by applicant]
WO WO2015186068A1
· 2015
[cited by applicant]
WO WO2015187649A1
· 2015
[cited by applicant]
WO WO2016014927A2
· 2016
[cited by applicant]
WO WO2016086088A2
· 2016
[cited by applicant]
WO WO2016086860A1
· 2016
[cited by applicant]
WO WO2016093515A1
· 2016
[cited by applicant]
WO WO2016144660A1
· 2016
[cited by applicant]
WO WO2016196941A1
· 2016
[cited by applicant]
WO WO2016210232A1
· 2016
[cited by applicant]
WO WO2017022768A1
· 2017
[cited by applicant]
WO WO2017059249A1
· 2017
[cited by applicant]
WO WO2017062311A1
· 2017
[cited by applicant]
WO WO2017079195A1
· 2017
[cited by applicant]
WO WO2017110317A1
· 2017
[cited by applicant]
WO WO2017114796A1
· 2017
[cited by applicant]
WO WO2017145151A1
· 2017
[cited by applicant]
WO WO2017161165A1
· 2017
[cited by applicant]
WO WO2017185549A1
· 2017
[cited by applicant]
WO WO2017218580A1
· 2017
[cited by applicant]
WO WO2018023205A1
· 2018
[cited by applicant]
WO WO2018023207A1
· 2018
[cited by applicant]
WO WO2018023208A1
· 2018
[cited by applicant]
WO WO2018023209A1
· 2018
[cited by applicant]
WO WO2018023210A1
· 2018
[cited by applicant]
WO WO2018047715A1
· 2018
[cited by applicant]
WO WO2018047716A1
· 2018
[cited by applicant]
WO WO2018052019A1
· 2018
[cited by applicant]
WO WO2018052020A1
· 2018
[cited by applicant]
WO WO2018089830A1
· 2018
[cited by applicant]
WO WO2018120069A1
· 2018
[cited by applicant]
WO WO2018132833A1
· 2018
[cited by applicant]
WO WO2018143258A1
· 2018
[cited by applicant]
WO WO2019152416A1
· 2019
[cited by applicant]
WO WO2020072497A1
· 2020
[cited by applicant]
WO WO2020197882A1
· 2020
[cited by applicant]
WO WO2022251491A1
· 2022
[cited by applicant]
“Nicotinamide Mononucleotide,” Item No. 16411 Product Information, Cayman Chemical (2014).
[cited by examiner]
“Non-antioxidant function of resveratrol”, Vitamins 90:286-289 (2016).
[cited by applicant]
ADP PubChem SID 134971804 deposited on Mar. 21, 2012.
[cited by applicant]
Ahmadibeni et al., “Solid-Phase Synthesis of Symmetrical 5′,5′-Dinucleoside Mono-, Di-, Tri-, and Tetraphosphodiesters,” Organic Letters, 9(22): 4483-4486 (2007).
[cited by applicant]
AMP PubChem SID 134970876 deposited on Mar. 21, 2012.
[cited by applicant]
Anastasi et al., “New antiviral nucleoside prodrugs await application,” Current medicinal chemistry, 10(18):1825-1843 (2003).
[cited by applicant]
Arany et al., “HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1?,” Nature, 451:1008-1012 (2008).
[cited by applicant]
Arbiser et al., “Overexpression of VEGF 121 in Immortalized Endothelial Cells Causes Conversion to Slowly Growing Angiosarcoma and High Lebel Expression of the VEGF Receptors VEGFR-1 and VEGFR-2 in Vivo,” Am J Pathol, 1…
[cited by applicant]
Asher et al., “SIRT1 Regulates Circadian Clock Gene Expression through PER2 Deacetylation,” Cell, 134:317 (2008).
[cited by applicant]
Askew et al., “Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease,” J Vasc Surg, 41(5):802-807 (2005).
[cited by applicant]
Atkinson et al., “Nicotinamide 6-Mercaptopurine Dinucleotide and Related Compounds: Potential Sources of 6-Mercaptopurine Nucleotide in Chemotherapy,” Nature, 196: 35-36 (1962).
[cited by applicant]
ATP PubChem SID 134972915 deposited on Mar. 21, 2012.
[cited by applicant]
Baker et al., “Use of the mouse aortic ring assay to study angiogenesis,” Nat Protoc, 7:89-104 (2012).
[cited by applicant]
Baltgalvis et al., “Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice,” Am J Physiol Heart Circ Physiol, 306:H1128-H1145 (2014).
[cited by applicant]
Barnea et al., “High-Fat Diet Delays and Fasting Advances the Circadian Expression of Adiponectin Signaling Components in Mouse Liver,” Endicrinology 150:161 (2009).
[cited by applicant]
Bassel-Duby et al., “Signaling Pathways in Skeletal Muscle Remodeling,” Annu Rev Biochem, 75:19-37 (2006).
[cited by applicant]
Bauer, “Polymorphism—A Critical Consideration in Pharmaceutical Development, Manufacturing, and Stability,” Journal of Validation of Technology, 14(5):15-23 (2008).
[cited by applicant]
Bazzanini et al., “Synthetic approaches to a mononucleotide prodrug of cytarabine,” Nucleosides, Nucleotides, and Nucleic Acids, 24(10-12):1635-1649 (2005).
[cited by applicant]
Belenky et al., “Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+,” Cell, 129(3):473-484 (2007).
[cited by applicant]
Berghaeuser et al., “A Simple Preparation of an Enzyme Reactor Producing Nicotinamidemononucleotide,” Biotechnology Letters, 3(7): 339-344 (1981).
[cited by applicant]
Bieganowski et al., “Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a preiss-handler independent route to NAD+ in fungi and humans,” Cell, 117:495-502 (2004).
[cited by applicant]
Blanco et al., “VEGF and notch in tip and stalk cell selection,” Cold Spring Harb Perspect Med, 3:a006569 (2013).
[cited by applicant]
Bobeck et al., “Advances in nucleoside monophosphate prodrugs as anti-HCV agents,” Antiviral Therapy—An Official Publication of the International Society for Antiviral Research, 15(7):935-950 (2010).
[cited by applicant]
Bogan et al., “Nicotinic acid, nicotinamide, and nicotinamide roboside: A molecuar evaluation of NAD+ precursos vitamins in human nutrition,” Annu Rev Nutr, 28:115-130 (2008).
[cited by applicant]
Booth et al., “Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models,” Physiol Rev, 71:541-585 (1991).
[cited by applicant]
Bordone et al., “Calorie restriction, SIRT1 and metabolism: understanding longevity,” Nat Rev Mol Cell Biol, 6:298-305 (2005).
[cited by applicant]
Borradaile et al., “NAD+, Sirtuins, and Cardiovascular Disease,” Current Pharmaceutical Design, 15(1):110-117 (2016).
[cited by applicant]
Borradaile et al., “Nicotinamide Phosphoribosyltransferase Imparts Human Endothelial Cells with Extended Replicative Lifespan and Enhanced Angiogenic Capacity in a High Glucose Environment,” Aging Cells, 8:100-112 (2009…
[cited by applicant]
Braidy et al., “Age related changes in NAD+ metabolism oxidative stress and sirt1 activity in wistar rats,” PLoS One, 6:e19194 (2011).
[cited by applicant]
Brittain et al., “X-Ray Diffraction of Pharmaceutical Materials,” Profiles of Drug Substances, Excipients, and Related Methodology, 30:273-319 (2003).
[cited by applicant]
Byrn et al., “Pharmaceutical solids: a strategic approach to regulatory considerations,” Pharmaceut Res, 12(7):945-954 (1995).
[cited by applicant]
Caira., Crystalline Polymorphism of Organic Compounds, Topics in Current Chemistry, 198: 163-208 (1998).
[cited by applicant]
Canto et al., “The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity,” Cell Metab, 15:838-847 (2012).
[cited by applicant]
Cardiac Medications, Heart.org, http://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heart-attack/cardiac-medications (2015).
[cited by applicant]
Cardus et al, “SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence,” Cardiovasc Res, 97:571-579 (2013).
[cited by applicant]
CAS Registry No. 108273-23-0 (1987).
[cited by applicant]
CAS Registry No. 108489-22-1 (1987).
[cited by applicant]
CAS Registry No. 1094-61-7 (1984).
[cited by applicant]
CAS Registry No. 150035-58-8 (1993).
[cited by applicant]
CAS Registry No. 321-02-8.
[cited by applicant]
CAS Registry No. 906748-40-1 (2006).
[cited by applicant]
Cattaneo-Pangrazzi et al., “The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-14…
[cited by applicant]
Cayman Chemical, “Beta-Nicotinamide mononucleotide,” Item No. 16411 Product Information (2014).
[cited by applicant]
Cayman Chemical, “Beta-Nicotinamide Mononucleotide,” Item No. 16411 Safety Data Sheet, Cayman Chemical (2015).
[cited by applicant]
Cebasek et al., “A novel staining method for quantification and 3D visualisation of capillaries and muscle fibres,” Eur J Histochem, 48(2):151-158 (2004).
[cited by applicant]
Chalkiadaki et al., “Muscle-specific SIRT1 Gain-of-Function Increases Slow-Twitch Fibers and Ameliorates Pathophysiology in a Mouse Model of Duchenne Muscular Dystrophy,” PLoS Genet, 10(7):e1004490 (2014).
[cited by applicant]
Chang et al., “Notch activation promotes endothelial survival through a PI3K-Slug axis,” Microvasc Res, 89:80-85 (2013).
[cited by applicant]
Chemical Cayman, “Nicotinic Acid Mononucleotide,” Item No. 32883.
[cited by applicant]
Cherney, “Osteoarthritis Medications List,” Healthline, https://www.healthline.com/health/osteoarthritis/medications-list#nsaids (2016).
[cited by applicant]
Chinsomboon et al., “The transcriptional coactivator PGC-1? mediates exercise-induced angiogenesis in skeletal muscle,” Proc Natl Acad Sci, 106(50):21401-21406 (2009).
[cited by applicant]
Cho et al., “Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection,” Tetrahedron, 67(30): 14 pages (2011).
[cited by applicant]
Chung et al., “Regulation of SIRT1 in cellular functions: Role of polyphenols”, Archives of Biochemistry and Biophysics 501(1):79-90 (May 5, 2010).
[cited by applicant]
Congiatu et al., “Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center,” Journal of medicinal chemistry, 49(2…
[cited by applicant]
Corda et al., “Functional aspects of protein mono-ADP-ribosylation,” EMBO J, 22(9):1953-1958 (2003).
[cited by applicant]
Costa et al., “The endothelial-erectile dysfunction connection: An essential update,” J Sex Med, 6:2390-2404 (2009).
[cited by applicant]
Cross et al., “Rules for the Nomenclature of Organic Chemistry. Section E: Sterohemistry,” Pure Appl Chem, 45(1):11-30, (1976).
[cited by applicant]
Das et al., “Nicotinamide mononucleotide, an NAD+ precursor, reverses age-associated decline in exercise capacity byincreasing skeletal muscle capillary density in a Sirt1-dependent manner.”: 2015 Hobart Programme, Nov.…
[cited by applicant]
Database Registry Chemical Abstracts, Database Accession No. 807266-77-9, CAS Registry No. 807266-77-9 (Jan. 2, 2005).
[cited by applicant]
De Souza, “Primer: Genome editing with engineered nucleases,” Nat Meth, 9(1):27 (2012).
[cited by applicant]
Dekker, Polymorphism in Pharmaceutical Solids, First Ed, pp. 184-208 (1999).
[cited by applicant]
Dekker, Polymorphism in Pharmaceutical Solids, First Ed, pp. 7-8 (1999).
[cited by applicant]
Diabetes Treatment, Drugs.com, https://www.drugs.com/diabetes-treatment.html (2018).
[cited by applicant]
Dimmeler et al., “Endothelial cell apoptosis in angiogenesis and vessel regression,” Res, 87:434-439 (2000).
[cited by applicant]
Dowden et al., “Chemical Synthesis of the Novel CA 2+ Messenger NAADP,” Nucleosides, Nucleotides and Nucleic Acids, 24(5-7):513-518 (2005).
[cited by applicant]
Duscha et al., “Capillary Density of Skeletal Muscle,” J Am Coll Cardiol, 33(7):1956-1963 (1999).
[cited by applicant]
Eliseev et al., “Comparative study of antihypoxic properties of some nucleosides and nucleotides.” Pharmaceutical Chemistry Journal 20.3 (1986): 160-162.
[cited by applicant]
Erion et al., “Design, Synthesis, and Characterization of a Series of Cytochrome P450 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver,” JACS Articles, 126: 5154-516…
[cited by applicant]
Escande et al., “Flavonoid apigenin is an inhibitor of the NAD+ ase CD38,” Diabetes, 62:1084-1093 (2013).
[cited by applicant]
Escudier et al., “Axitinib for the Management of Metastatic Renal Cell Carcinoma,” Drugs R D, 11(2):113-126 (2011).
[cited by applicant]
Extended European Search Report for EP Application No. 16833957.0 dated Dec. 21, 2018.
[cited by applicant]
Extended European Search Report for EP Application No. 16852711.7 dated Feb. 11, 2019.
[cited by applicant]
Extended European Search Report for EP Application No. 17883855.3 dated Dec. 15, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. 23197016.1 dated Oct. 18, 2023.
[cited by applicant]
Fan et al., “Exercise Mimetics: Impact on Health and Performance”, Cell Metabolism 25:242-247 (Feb. 7, 2017).
[cited by applicant]
Fang et al., “Defective Mitophagy in XPA via PARP-1 Hyperactivation and NAD+/SIRT1 Reduction,” Cell, 157(4):882-896 (2014).
[cited by applicant]
Firestein et al., “The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth,” PLoS One, 3(4):e2020 (2008).
[cited by applicant]
Galli et al., “The Nicotinamide Phosphoribosyltransferase: A Molecular Link between Metabolism, Inflammation, and Cancer”, Cancer Research, 70(1), pp. 8-11, 2010.
[cited by applicant]
Garten et al., “Nampt: Linking NAD biology, metabolism, and cancer,” Trends Endocrinol Metab, 20(3):130-138 (2009).
[cited by applicant]
Gavande et al., “DNA repair targeted therapy: The past or future of cancer treatment?,” Pharmacology & Therapeutics, 160:65-83 (2016).
[cited by applicant]
Gockel et al., “Synthesis of an oligonucleotide with a nicotinamide mononucleotide residue and its molecular recognition in DNA helices,” Organic & Biomolecular Chemistry, 13(41):10303-10309 (2015).
[cited by applicant]
Gomes et al., “Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication druing Aging,” Cell, 155(7):1624-1638 (2013).
[cited by applicant]
Grieger et al., Adeno-associated virus as a gene therapy vector: Vector development, production and clinical application,s: Advances in Biochemical Engineering/Biotechnology, 99:119-145 (2005).
[cited by applicant]
Guarani et al., “Acetylation-dependent regulation of endothelial notch signalling by the SIRT1 deacetylase,” Nature 473(7346):234-238 (2011).
[cited by applicant]
Guest et al., “Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age in Cerebrospinal Fluid,” PLOS One, 9(1):e85335 (2014).
[cited by applicant]
Harasata et al., “Septal glucagon-like peptide I receptor expression determines suppression of cocaine-induced behavior,” Neuropsychopharmacology, 40:1969-1978 (2015).
[cited by applicant]
Hardie, “Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status”, Endocrinology 144(12): 5179-5183 (2003).
[cited by applicant]
Harrison et al., “Inhibition of Platelet Aggregation and the Platelet Release Reaction By alpha, omega Diadenosine polyphosphates,” FEBS Letts 54(1):57-60 (1975).
[cited by applicant]
Hart et al., “Resveratrol enhances exercise training responses in rats selectively bred for high running performace”, Food and Chemical Toxicology 61:53-59 (2013).
[cited by applicant]
Hirayama, Yuukikagoubutsu Kessyo sakusei Handbook—Genri to Know-how—(Handbook for Preparation of Crystals of Organic Compounds—Principle and Know-how—), Maruzen Co. Ltd., pp. 37-84 (2008).
[cited by applicant]
Hood, “Plasticity in skeletal, cardiac, and smooth muscle,” J Appl Physiol, 90:1137-1157 (1985).
[cited by applicant]
Huang et al., “Metabolomics-driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson's disease,” Journal of Neurochemistry, 150: 282-295 (2019).
[cited by applicant]
Imai et al., “NAD+ and sirtuins in aging and disease,” Trends in Cell Biol, 24(8):464-471 (2014).
[cited by applicant]
Imai et al., “Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase,” Nature, 403:795-800 (2000).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/AU17/51435 dated Mar. 6, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/45855 dated Nov. 14, 2016.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/54776 dated Jan. 25, 2017.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/15672 dated May 15, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/23318 dated Jun. 24, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/31124 dated Oct. 6, 2022.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US22/31124 dated Aug. 5, 2022.
[cited by applicant]
Kamel et al., “Pharmaceutical significance of cellulose: A review”, Express Polym Letters 2(11): 758-778 (2008).
[cited by applicant]
Kohsaka et al., “high-Fat Diet Disrupts Behavioral and Molecular Circadian Rhythms in Mice,” Cell Metab, 6:414 (2007).
[cited by applicant]
Kolluru et al., “Endothelial dysfunction and diabetes: Effects on angiogenesis, vascular remodeling, and wound healing,” Int J Vasc Med, 918267, 1-30 (2012).
[cited by applicant]
Koltai et al., “Exercise alters SIRT1, SIRT6, Nad and NAMPT levels in skeletal muscle of aged rats”, Mechanisms of Ageing and Development 131(1):21-28 (Nov. 12, 2009).
[cited by applicant]
Koni et al., “Conditional vascular cell adhesion molecule 1 deletion in mice: Impaired lymphocyte migration to bone marrow,” J Exp Med, 193(6):741-753 (2001).
[cited by applicant]
Korff et al., “Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation,” J Cell Biol, 143(5):1341-1352 (1998).
[cited by applicant]
Kuznetsov et al., “Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells,” Nat Protoc, 3(6):965-976 (2008).
[cited by applicant]
Lanza et al., “Primary Coronary Microvascular Dysfunction,” Circulation, 121:2317-2325 (2010).
[cited by applicant]
Le Couteur et al., “A Vascular Theory of Aging,” Journal of Gerontology, 65A(10):1025-1027 (2010).
[cited by applicant]
Lee et al., “A Chemical Synthesis of Nicotinamide Adenine Dinucleotide (NAD+),” Chemical Communications (Cambridge), 8: 729-730 (1999).
[cited by applicant]
Lee, “A practical guide to pharmaceutical polymorph screening & selection,” Asian Journal of Pharmaceutical Science 9(4):163-175 (2014).
[cited by applicant]
Leisvuori et al. “5′, 5′-Phosphodiesters and esterase labile triesters of 2′-C methylribonucleosides”, ARKIVOC: Online Journal of Organic Chemistry (2012).
[cited by applicant]
Limbourg et al., “Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia,” Nat Protoc, 4(12):1737-1746 (2009).
[cited by applicant]
Lin et al., “Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease,” Curr Opin Cell Biol, 15:241-246 (2003).
[cited by applicant]
Lin et al., “Transcriptional co-activator PGC-1? drives the formation of slow-twitch muscle fibres,” Nature, 418:797-801 (2002).
[cited by applicant]
Liu et al., “A Novel Preparation of Nicotinamide Mononucleotide,” Nucleosides & Nucleotides, 13(5): 1215-1216 (1994).
[cited by applicant]
Liu et al., “Enzymatic synthesis of polymers containing nicotinamide mononucleotide,” Nucleic Acids Research, 23(18):3742 (1995).
[cited by applicant]
Liu et al., “Synthesis of Phosphodiester-type Nicotinamide Adenine Dinucleotide Analogs,” Tetrahedron, 65(40): 8378-8383 (2009).
[cited by applicant]
Makarov et al., “Syntheses and chemical properties of B-nicotinamide riboside and its analogues and derivatives,” Beilstein J Org Chem, 15: 401-430 (2019).
[cited by applicant]
Massudi et al., “Age-associated changes in oxidative stress and NAD+ metabolism in human tissue,” PloS One, 7(7): e42357 (2012).
[cited by applicant]
McCormick, “The pathology vascular (“arteriovenous”) malformations,” J Neurosurg, 24:807-816 (1966).
[cited by applicant]
McGuigan et al., “Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase,” FEBS Letters, 351: 11-14 (1994).
[cited by applicant]
McGuigan et al., “Phosphorodiamidates as a Promising New Phosphate Prodrug Motif for Antiviral Drug Discovery: Application to Anti-HCV Agents,” Journal of Medicinal Chemistry, 54: 8632-8645 (2011).
[cited by applicant]
Medications for Dermatitis, Drugs.com, https://www.drugs.com/condition/dermatitis.html (2018).
[cited by applicant]
Medications for Obesity, Drugs.com, https://www.drugs.com/condition/obesity.html (2018).
[cited by applicant]
Medications for Peripheral Neuropathy, Drugs.com, https://www.drugs.com/condition/peripheral-neuropathy.html (2018).
[cited by applicant]
Medications for Thrombotic/Thromboembolic Disorder, Drugs.com, https://www.drugs.com/condition/thrombotic-thromboembolic-disorder.html (2018).
[cited by applicant]
Menissier de Murcia et al., “Functional Interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse,” EMBO J, 22(9):2255-2263 (2003).
[cited by applicant]
Mersmann et al., “Aspartoacylase-LacZ Knockin Mice: An Engineered Model of Canavan Disease,” PLoS One, 6(5):e20336 (2011).
[cited by applicant]
Migaud et al., “Probing Aplysia californica Adenosine 5′-Diphosphate Ribosyl Cyclase for Substrate Binding Requirements: Design of Potent Inhibitors,” Biochemistry, 38:9105-9114 (1999).
[cited by applicant]
Mikhailopulo et al., “Synthesis of glycosides of nicotinamide and nicotinamide mononucleotide,” Synthesis, 5:388-389 (1981).
[cited by applicant]
Mitchell et al., “The SIRT1 Activator SRT1720 Extends Lifespan and Improves Health of Mice Fed a Standard Diet,” Cell Reports, 6: 836-843 (2014).
[cited by applicant]
Moazed, “Enzymatic activities of Sir2 and chromatin silencing,” Curr Opin Cell Biol, 13(2):232-238 (2001).
[cited by applicant]
Montgomery et al., “Synthesis of Potential Anticancer Agents. XXVIII. Simple Esters of 6-Mercaptopurine Ribonucleotide2,” The Journal of Organic Chemistry, 26(6):1929-1933 (1961).
[cited by applicant]
Morscher et al., “Semi-quantitative multispectral optoacoustic tomography (MSOT) for volumetric PK imaging of gastric emptying,” Photoacoustics, 2:103-110 (2014).
[cited by applicant]
Mouchiroud et al., “NAD+ metabolism, a therapeutic target for age-related metabolic disease,” Crit Rev Biochem Mol Biol, 48(4):397-408 (2013).
[cited by applicant]
Mouchiroud et al., “The NAD+/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial URP and FOXO Signaling,” Cell, 154:430-441 (2013).
[cited by applicant]
Moynihan et al., “Increased dosage of mammalian Sir2 in pancreatic β cells enhances glucose-stimulated insulin secretion in mice,” Cell Metab, 2:105-117 (2005).
[cited by applicant]
Muzumdar et al., “A Global Double-Fluorescent Cre Reporter Mouse,” Genesis, 45:593-605 (2007).
[cited by applicant]
Nakahata et al., “The NAD+-Dependent Deacetylase SIRT1 Modulates CLOCK-Mediated Chromatin Remodeling and circadian Control,” Cell, 134(2):329 (2008).
[cited by applicant]
Nakai et al., Shin Seizaigaku (New Pharmacy), Nanzando Co. Ltd., 1st Edition, 2nd Printing, pp. 102-104, 217-236 (1984).
[cited by applicant]
Nikiforov et al., “Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells,” The Journal of Biological Chemistry, 286 (24):21767-21778 (2011).
[cited by applicant]
Noseda et al., “Notch Activation Induces Endothelial Cell Cycle Arrest and Participates in Contact Inhibition: Role of P21Cip1 Repression,” Mol Cell Biol, 24(20):8813-8822 (2004).
[cited by applicant]
Novelle et al., “Resveratrol supplementation: Where are we now and where should we go?”, Ageing Research Reviews 21:1-15 (2015).
[cited by applicant]
Office Action for Chinese Application No. 201780086403.4 dated Apr. 6, 2022.
[cited by applicant]
Office Action for Chinese Application No. 201780086403.4 dated Dec. 29, 2022.
[cited by applicant]
Office Action for Japanese Application No. 2019-533084 dated Jun. 27, 2022.
[cited by applicant]
Office Action for Japanese Application No. 2019-533084 dated Mar. 30, 2023.
[cited by applicant]
Office Action for Japanese Application No. 2019-533084 dated Oct. 27, 2021.
[cited by applicant]
Office Action for Korean Application No. 10-2019-7021500 dated Feb. 28, 2023.
[cited by applicant]
Oomen et al., “Vascular endothelial growth factor A (VEGF-A) induces endothelial and cancer cell migration through direct binding to integrin ?9β1,” J Biol Chem, 286(2):1083-1092 (2011).
[cited by applicant]
Pearson et al., “Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction with out extending lifespan,” Cell Metab, 8(2):157-168 (2008).
[cited by applicant]
Pencina et al., “MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of Beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Old…
[cited by applicant]
Pencina et al., “Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study”, The Journal of Clinical Endocrinology & Metabolism, Feb. 6, 2023, 00, pp. 1-13.
[cited by applicant]
Pertusati et al., “Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy,” Antivir Chem Chemother, 22(5):181-203 (2012).
[cited by applicant]
Petrelli et al., “NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications,” Current Medicinal Chemistry, 18: 1973-1992 (2011).
[cited by applicant]
Pette et al., “Myosin isoforms, muscle fiber types, and transitions,” Microsc Res Tech, 50:500-509 (2000).
[cited by applicant]
Pfleiderer et al., “Zum Wirkungsmechanismus von Dehydrogenasen V. Uber die Bedeutung des Adenosindiphosphatrestes im Nicotinamid-Adenin-Dinucleotid,” Biochimica et Biophysica Acta, 73:39-49 (1963).
[cited by applicant]
Picard et al., “Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-y,” Nature, 429:771-776 (2004).
[cited by applicant]
Potente et al., “Emerging roles of SIRT1 in vascular endothelial homeostasis,” Cell Cycle, 7:2117-2122 (2008).
[cited by applicant]
Potente et al., “SIRT1 Controls Endothelial Angiogenic Functions During Vascular Growth,” Genes & Development, 21: 2644-2658 (2007).
[cited by applicant]
Preitner et al., “The Orphan Nuclear Receptor REV-ERBa Controls Circadian Transcription within the Positive Limb of the Mammalian circadian Oscillator,” Cell, 110:251 (2002).
[cited by applicant]
Price et al., “SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function,” Cell Metab, 15:675-690 (2012).
[cited by applicant]
Prior et al., “Sacropenia is associated with lower skeletal muscle capillarization and exercise capacity in older adults,” J Gerontol A Biol Sci Med Sci, 71(8):1096-1101 (2016).
[cited by applicant]
PubChem SID: 347731451 “Substance Record 321-02-8” retrieved online <https://pubchem.ncbi.nlm.nih.gov/substance/347731451>: 6 pages (Create Date Oct. 23, 2017).
[cited by applicant]
Puech et al., “Nucleotidic prodrugs of anti-HIV dideoxynucleosides”, Bioorganic & medicinal chemistry letters 2(6): 603-606 (1992).
[cited by applicant]
Rajman et al., “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence,” Cell Metabolism, 27(3): 529-547 (2018).
[cited by applicant]
Ramsey et al., “Cicadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis,” Science, 324(5927):651-654 (2009).
[cited by applicant]
Rechsteiner et al., “The Biosynthesis and Turnover of Nicotinamide Adenine Dinucleotide in Enucleated Culture Cells”, The Journal of Cellular Physiology 84(3):409-421 (Dec. 1, 1974).
[cited by applicant]
Redpath et al., “Nicotinamide Benzimidazolide Dinucleotides Non-Cyclisable Analogues of NAD+,” Synlett, 25:2331-2336 (2014).
[cited by applicant]
Repress et al., “Transthoracic echocardiography in mice,” Journal of Visualized Experiments, 39:e1738 (2010).
[cited by applicant]
Riemschneider et al., “Zur Beeinflussung von Stoffwechselvorgangen durch unphysiologische Verbindungen, IV: Nicotinylaminosaureester und Nucleosid-Deritvate,” Insect repellent science, 41(3):99-106 (1976).
[cited by applicant]
Rodgers et al., “Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1,” Nature, 434:113-118 (2005).
[cited by applicant]
Rodionova et al., “Metabolic and bactericidal effects of targeted suppression of NadD and NadE enzymes in mycobacteria,” mBio, 5(1):e00747-13 (2014).
[cited by applicant]
Rose et al., “GYY4137, a Novel Water-Soluble, H2S-Releasing Molecule,” Methods in Enzymology, 554:143-167 (2015).
[cited by applicant]
Roskar et al., “Analytical Methods for Quantification of Drug Metabolites in Biological Samples,” IntechOpen, Chapter 4:79-126 (2012).
[cited by applicant]
Ross, “Visualization of mitochondrial respiratory function using cytochrome C oxidase / succinate dehydrogenase (COX/SDH) double-labeling histochemistry,” J Vis Exp, 57:e3266 (2011).
[cited by applicant]
Rowe et al., “Running Forward: New Frontiers in Endurance Exercise Biology,” Circulation, 129(7):798-810 (2014).
[cited by applicant]
Rudic et al., “BMAL1 and CLOCK, Two Essential Components of the Circadian Clock, Are Involved in Glucose Homeostasis,” PLoS Biol, 2:e377 (2004).
[cited by applicant]
Rutter et al., “Regulation of Clock and NPAS2 DNA Binding by the Redox State of NAD Cofactors,” Science, 293(5529):510 (2001).
[cited by applicant]
Sarma et al., “Investigations of Inter- and Intramolecular Interactions in Flavin-Adenine Dinucleotide by Proton Magnetic Resonance,” Biochemistry, 7(12):4359-4367 (1968).
[cited by applicant]
Sato et al., “A Functional Genomics Strategy Reveals Rora as a Component of the Mammalian Circadian Clock,” Neuron, 43:527 (2004).
[cited by applicant]
Sauve et al., “Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry,” Biochemistry, 42(31):9249-9256 (2003).
[cited by applicant]
Schwartz et al., “The Effect of Growth Conditions on NAD+ and NADH Concentrations and the NAD+: NADH Ratio in Normal and Transformed Fibroblasts,” J Biol Chem, 249(13): 4138-4143 (1974).
[cited by applicant]
Sharma et al., “X-ray diffraction: a powerful method of characterizing nanomaterials,” Recent Research in Science and Technology, 4:77-79 (2012).
[cited by applicant]
Shioji, Kokei Seizai no Seizo Gijutsu (Manufacture Technology of Solid Tablet), CMC Publishing Co. Ltd., Popular Edition, 1st Printing, pp. 9-14 (2003).
[cited by applicant]
Sleep Disorders: Medications for Circadian Rhythm Disorders, WebMD, https://www.webmd.com/sleep-disorders/circadian-rhythm-disorder-medications#1 (2018).
[cited by applicant]
Smith et al., “A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences,” Nucleic Acids Research, 34(22):e149 (2006).
[cited by applicant]
Smith et al., “A phylogenetically conserved NAD+-dependent protein decetylase activity in the Sir2 protein family,” Proc Natl Acad Sci, 97(12):6658-6663 (2000).
[cited by applicant]
Soto-Gamez et al., “Therapeytic interventions for aging: the case of cellular senescence,” Drug Discovery Today, 22(5):786-795 (2017).
[cited by applicant]
Stein et al., “Expression of nampt in hippocampal and cortical excitatory neurons is critical for cognitive function,” J Neurosci, 34(17): 5800-5815 (2014).
[cited by applicant]
Stein et al., “Scientific ablation on Nampt in adult neural stem cells recapitulates their functional defects during aging,” EMBO J, 33(12):1321-1340 (2014).
[cited by applicant]
Stieger et al., “7:Recrystallization of Active Pharmaceutical Ingredients,” Crystallization—Science and Technology, 183-204 (2012).
[cited by applicant]
Takada, “API form screening and selection in drug discovery stage”, Pharm Stage, 6(10):20-25. (2007).
[cited by applicant]
Takahashi et al., “The Genetics of Mammalian Circadian Order and Disorder: Implications for Physiology and Disease,” Nat Rev Genet, 9(10):764 (2008).
[cited by applicant]
Tan et al., “Precision Editing of Large Animal Genomes,” Adv Genet, 80: 37-97 (2012).
[cited by applicant]
The Chemical Society of Japan Ed., 4th Edition Jikken Kagaku Kouza 1 Kihon Sousa I (4th Edition Experimental Chemistry 1 Basic Operation I), Maruzen Co. Ltd., 2nd Printing, pp. 184-186 (1996).
[cited by applicant]
Thorpe et al., “Lipoamide Dehydrogenase from Pig Heart. Pyridine Nucleotide Induced Changes in Monoalkylated Two-Electron Reduced Enzyme,” Biochemistry, 20: 1507-1513 (1981).
[cited by applicant]
Turek et al., “Obesity and Metabolic Syndrome in Circadian Clock Mutant Mice,” Science, 308:1043 (2005).
[cited by applicant]
Turner et al., “Enhancement of muscle mitochondrial oxidative capacity and alterations in insulin action are lipid species dependent,” Diabetes, 58:2547-2554 (2009).
[cited by applicant]
Uddin et al., “Head to Head Comparison of Short-Term Treatment with the NAD+ Precursos Nicotinamide Mononucleotide (NMN) and 6 Weeks of Exercise in Obese Female Mice,” Front Pharmacol, 7(258):1-11 (2016).
[cited by applicant]
United States Department of Health and Human Services. “Guidance for Industry Pyrogen and Endotoxin Testing: Questions and Answers,” pp. 1-10 (2012).
[cited by applicant]
United States Pharmacopeia General Chapter <151> Pyrogen Test, 2 pages.
[cited by applicant]
Urnov et al., “Genome editing with engineered zinc finger nucleases,” Nat Rev Genet, 11(9):636-646 (2010).
[cited by applicant]
Van Beijnum et al., “Isolation of endothelial cells from fresh tissues,” Nat Protoc, 3:1085-1091 (2008).
[cited by applicant]
Vasko et al., “Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: Relevance to fibrosis of vascular senescence,” J Am Soc Nephrol, 25:276-291 (2014).
[cited by applicant]
Verdin et al., “NAD+ in aging, metabolism, and neurodegeneration”, Science 350(6265):1208-1213 (Dec. 4, 2015).
[cited by applicant]
Vinciguerra et al., “SirT1 in muscle physiology and disease: lessons from mouse models”, Disease Models & Mechanisms 3:298-303 (2010).
[cited by applicant]
Walt et al., “An Efficient Chemical and Enzymatic Synthesis of Nicotinamide Adenine Dinucleotide (NAD+),” Journal of the American Chemical Society, 106(1): 234-239 (1984).
[cited by applicant]
Wang et al., “A local mechanism mediates NAD-dependent protection of axon degeneration,” J Cell Biol, 170(3):349-355 (2005).
[cited by applicant]
Wang et al., “Intracellular NAMPT-NAD+-SIRT1 Cascade Improves Post-Ischaemic Vascular Repair by Modulating Notch Signalling in Endothelial Progenitors,” Cardiovascular Research, 104: 477-488 (2014).
[cited by applicant]
Wang et al., “P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage,” Cell, 158(6):1324-1334 (2014).
[cited by applicant]
Wei et al., “Aortopathy in a mouse model of marfan syndrome is not mediated by altered transforming growth factor β signaling,” J Am Heart Assoc, 1-14 (2017).
[cited by applicant]
Wen et al., “Ca2+/calmodulin-dependent protein kinase kinase β phosphorylation of Sirtuin 1 in endothelium is atheroprotective,” Proc Natl Acad Sci, 110:e2420-e2427 (2013).
[cited by applicant]
Wiemer et al., “Prodrugs of Phosphnates and Phosphates: Crossing the Membrane Barrier,” Topics in Current Chemistry, 360:115-160 (2014).
[cited by applicant]
Woenckhaus, “Synthesen und biochemische Eigenschaften wassertoffubertragender Coenzye modelle,” Chemische Berichte, 97(9):2439-2446 (1964).
[cited by applicant]
Wound Care Medications, GoodRx.com, https://www.goodrx.com/wound-care/drugs (2018).
[cited by applicant]
Yamada et al., “The simultaneous measurement of nicotinamide adenine dinucleotide and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry,” Analytical Biochemistry, 352:282-285 (2…
[cited by applicant]
Yang et al., “NAD+-dependent Deacetylase SIRT3 Regulates Mitochondrial Protein Synthesis by Deacetylation of the Ribosomal Protein MRPL10,” J Biol Chem, 285: 7417-7429 (2010).
[cited by applicant]
Yoshino et al., “Nicotinamide Mononucleotide, a Key NAD+ Intermediate, Treats the Pathology of Diet- and Age-Induced Diabetes in Mice,” Cell Metab, 14(4): 528-536 (2011).
[cited by applicant]
Zhang et al., “Hydrogen Sulfide, the Next Potent Preventive and Therapeutic Agent in Aging and Age-Associated Diseases,” Molecular and Cellular Biology, 33(6): 1104-1113 (2013).
[cited by applicant]
Zhang et al., “Liung endothelial HO-1 targeting in vivo using lentiviral miRNA regulates apoptosis and autophagy during oxidant injury,” FASEB J, 27:4014-4058 (2013).
[cited by applicant]
Zhao et al., “SIRT1 and exercises”, Chinese Journal of Gerontology, vol. 31, No. 5, published on May 4, 2011, pp. 906-910.
[cited by applicant]
Zhu et al., “A hydrazine coupled cycling assay validates the decrease in redox ratio under starvation in
[cited by applicant]
Bauer, “Pharmaceutical solids-the amorphous phase.” Journal of Validation Technology 15.3 (2009): 63.
[cited by applicant]
Extended European Search Report for EP Application No. 22812156.2 dated Apr. 14, 2025.
[cited by applicant]
Cited By (1)